Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.263
+0.004 (1.55%)
At close: Nov 4, 2024, 4:00 PM
0.264
+0.001 (0.27%)
After-hours: Nov 4, 2024, 7:55 PM EST
Lyra Therapeutics Employees
Lyra Therapeutics had 88 employees as of December 31, 2023. The number of employees increased by 30 or 51.72% compared to the previous year.
Employees
88
Change (1Y)
30
Growth (1Y)
51.72%
Revenue / Employee
$20,682
Profits / Employee
-$1,152,159
Market Cap
17.21M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88 | 30 | 51.72% |
Dec 31, 2022 | 58 | 5 | 9.43% |
Dec 31, 2021 | 53 | 15 | 39.47% |
Dec 31, 2020 | 38 | 0 | - |
Dec 31, 2019 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Cara Therapeutics | 55 |
AIM ImmunoTech | 28 |
GeoVax Labs | 17 |
Cocrystal Pharma | 12 |
Innovative Eyewear | 11 |
NanoViricides | 7 |
Synlogic | 6 |
LYRA News
- 20 days ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 5 weeks ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - 3 'Buy-Rated' Biotech Stocks Under $10 - Seeking Alpha
- 6 months ago - Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire